Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery (“Sygnature”), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes. As part of the agreement, Pathios
MoreThe space occupied by a drug molecule in three dimensions, and how it fits into the target, is an important
MoreSygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has recruited four key individuals to boost its
MorePathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and
More